• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PainReform Ltd.

    4/24/24 4:32:05 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    SC 13G 1 ea0204591-13gintra_pain.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    PainReform Ltd.

     

    (Name of Issuer)

     

    Ordinary shares, par value NIS 0.30 per share

     

    (Title of Class of Securities)

     

    IL0011651580

    (CUSIP Number)

     

    April 15, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. IL0011651580

     

    1.

    Names of Reporting Persons.

     

    Mitchell P. Kopin

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    201,600

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    193,500

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    201,600 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    7.9% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 2 of 8

     

     

    CUSIP No. IL0011651580

     

    1.

    Names of Reporting Persons.

     

    Daniel B. Asher

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    201,600

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    193,500

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    201,600 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    7.9% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 3 of 8

     

     

    CUSIP No. IL0011651580

     

    1.

    Names of Reporting Persons.

     

    Intracoastal Capital LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    201,600

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    193,500

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    201,600 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    7.9% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    Page 4 of 8

     

     

    Item 1.

     

    (a)Name of Issuer

     

    PainReform Ltd. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    65 Yigal Alon St.

    Tel Aviv 6744316 Israel 4710

     

    Item 2.

     

    (a)Name of Person Filing

     

    (b)Address of Principal Business Office or, if none, Residence

     

    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Ordinary shares, par value NIS 0.30 per share (the “Ordinary Shares”).

     

    (e)CUSIP Number

     

    IL0011651580

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on April 15, 2024 (the “SPA”) (as disclosed in the Form 6-K filed by the Issuer with the Securities and Exchange Commission on April 17, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 224,887 Ordinary Shares, which consisted of (i) 222,500 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 2,387 Ordinary Shares issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such Ordinary Shares in the aggregate represent beneficial ownership of approximately 9.99% of the Ordinary Shares, based on (1) 2,026,243 Ordinary Shares outstanding on April 11, 2024 as reported by the Issuer, plus (2) 222,500 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 2,387 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 87,613 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Ordinary Shares, (II) 312,500 Ordinary Shares issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Ordinary Shares and (III) 3,850 Ordinary Shares issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Ordinary Shares. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 628,850 Ordinary Shares.

     

    (ii) As of the close of business on April 24, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 201,600 Ordinary Shares, which consisted of (i) 111,600 Ordinary Shares held by Intracoastal and (ii) 90,000 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1, and all such Ordinary Shares in the aggregate represent beneficial ownership of approximately 7.9% of the Ordinary Shares, based on (1) 2,026,243 Ordinary Shares outstanding on April 11, 2024 as reported by the Issuer, plus (2) 447,500 Ordinary Shares issued at the closing of the transaction contemplated by the SPA and (3) 90,000 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 312,500 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Ordinary Shares and (II) 3,850 Ordinary Shares issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Ordinary Shares. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 517,950 Ordinary Shares.

     

    Page 6 of 8

     

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:          0        .

     

    (ii) Shared power to vote or to direct the vote:          201,600        .

     

    (iii) Sole power to dispose or to direct the disposition of          0        .

     

    (iv) Shared power to dispose or to direct the disposition of          193,500        .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: April 24, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 8 of 8

     

     

    Get the next $PRFX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

      As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on the Tel Aviv Stock Exchange, announced the achievement of a first milestone in the transaction involving the sale of its DeepSolar operations to PainReform (NASDAQ:PRFX). According to the agreement, which was completed in March 2025, Blade Ranger received a package of securities that included, among o

      5/27/25 12:12:00 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

      TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP). The project will utilize PainReform's proprietary DeepSolar™ platform, an AI-powered optimization solution designed to enhance operational efficiency and energy yield at utility-scale solar facilities. The pilot will be conducted at Econergy's 92-megawatt (MW) photovoltaic plant in Parau, Romania—one of the country's largest operational solar projects. This initiative marks the first phase of a broader collaboration between PainReform and Econergy, designed to demo

      5/7/25 4:30:00 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

      TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven software solutions designed to optimize solar energy usage in residential and utility-scale solar power plants. This strategic expansion marks an important milestone in PainReform's long-term diversification strategy, aimed at tapping into high-growth, tech-enabled markets. With global solar capacity a

      4/10/25 8:30:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

      SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

      11/14/24 4:25:42 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

      SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

      11/13/24 11:18:32 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

      SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

      8/29/24 4:00:27 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    SEC Filings

    See more
    • SEC Form EFFECT filed by PainReform Ltd.

      EFFECT - PAINREFORM LTD. (0001801834) (Filer)

      5/12/25 12:15:17 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by PainReform Ltd.

      424B3 - PAINREFORM LTD. (0001801834) (Filer)

      5/9/25 4:39:05 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PainReform Ltd.

      6-K - PAINREFORM LTD. (0001801834) (Filer)

      5/7/25 4:41:40 PM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    See more
    • PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

      HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

      3/18/21 9:15:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

      HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

      1/6/21 8:30:00 AM ET
      $PRFX
      Biotechnology: Pharmaceutical Preparations
      Health Care